Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 30, 2026

DeepSeek's DSpark Just Made Nvidia's Most Important New Bet Harder to Close

View original at nasdaq.com
DeepSeek's DSpark Just Made Nvidia's Most Important New Bet Harder to Close Key Points Nvidia's GPU business is not in question. What is in question is the incremental hardware layer Nvidia is now trying to sell on top of it…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full-year fiscal 2027 Data Center revenue consensus sits near $343 billion.

    60% confidence
  • Throughput at a fixed service level improved 51%.

    60% confidence
  • Per-user generation speed improved 60% to 85% on DeepSeek-V4-Flash and 57% to 78% on V4-Pro over the prior baseline.

    60% confidence
  • Consensus Data Center gross margin for fiscal 2027 is projected at 76.3%, slightly below fiscal 2024 and 2025 levels.

    60% confidence
  • The Groq 3 LPX and Vera Rubin NVL72 combination delivers up to 35 times higher inference throughput per megawatt for trillion-parameter models.

    60% confidence
  • The AWS-Cerebras disaggregated inference solution delivers inference an order of magnitude faster than existing GPU-only solutions.

    60% confidence
  • MLA compression reduced KV cache requirements by over 90% across DeepSeek's model generations.

    60% confidence
  • Confirmed more than $1 trillion in combined Blackwell and Rubin purchase orders through 2027.

    60% confidence
  • DeepSeek-V4-Pro needs roughly 10% of the memory that V3.2 required for million-token conversations.

    60% confidence
  • Stock Advisor's total average return is 902%, a market-crushing outperformance compared to 207% for the S&P 500.

    60% confidence

Data points we hold from this source

Stock Advisor · market share902 percent_total_average_return
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
DeepSeek's DSpark Just Made Nvidia's Most Important New Bet Harder to Close — Source | Via News | Finance Via News